From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Keytruda was the first immunotherapy called a checkpoint inhibitor that was approved for first‐line treatment of lung cancer. Below you’ll find common questions and answers about Keytruda to ...

However while melanoma is relatively rare, lung cancer is by far the UK’s biggest cancer killer. It causes 22% of all cancer deaths in men and women, more than breast and bowel cancer combined.

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug ...

In addition, treating lung cancer patients with Keytruda improved quality of life. Among those who got the immunotherapy drug, only 18% experienced severe side effects, compared with 41% on ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...

Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer ...

LOS ANGELES (KABC) -- Researchers call the drug Keytruda a new and exciting option in treating the leading cause of cancer deaths worldwide. One local lung cancer patient experienced what doctors ...

Immunotherapy: A new weapon against cancer 06:58. Rates of serious side effects were similar, but twice as many in the Keytruda group dropped out because of them.

Keytruda is now the second FDA-approved PD-1 inhibitor in lung cancer, and first across all NSCLC histologies. The PD-1 agent Opdivo (nivolumab) was approved in March 2015 for patients with NSCLC who ...

Keytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey — costing about $150,000 a year for a course of treatment. It’s approved for use with a specific test ...

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later, compared with about half of people who only got chemotherapy.